Key Points
- Stabilize ABCs; treat life‑threatening derangements immediately.
- Confirm diagnosis early with highest‑yield imaging/labs.
- Initiate guideline‑based therapy and escalate by response.
- Plan disposition and follow‑up explicitly.
Clinical Synopsis & Reasoning
Immune TTP is a microangiopathy from severe ADAMTS13 deficiency. Treat presumptively when suspected: daily plasma exchange plus high‑dose corticosteroids. Add caplacizumab early to shorten time to platelet recovery and reduce exacerbations; introduce rituximab to target the autoantibody. Monitor for relapse and complications.
Treatment Strategy & Disposition
Immune TTP is a microangiopathy from severe ADAMTS13 deficiency. Treat presumptively when suspected: daily plasma exchange plus high‑dose corticosteroids. Add caplacizumab early to shorten time to platelet recovery and reduce exacerbations; introduce rituximab to target the autoantibody. Monitor for relapse and complications.
Epidemiology / Risk Factors
- Risk varies by comorbidity and precipitating factors
Initial Targets
| Parameter | Target/Action |
|---|---|
| Hemodynamics | Maintain perfusion; avoid hypotension |
| Monitoring | Serial exam, labs, and imaging |
| Therapy | Start early, reassess, de‑escalate when appropriate |
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| CBC | Screen leukocytosis/anemia | Context‑specific | Trend response |
| BMP | Electrolytes/renal function | Derangements common | Replace K+/Mg2+ |
| Key imaging | Condition‑specific (CTA/MRI/Endoscopy) | See text | Do not delay when red flags |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Therapeutic plasma exchange | Immunotherapy | Immediate | First‑line with steroids | Access/bleeding risks |
| Caplacizumab | anti‑vWF nanobody | Hours | Add when iTTP likely | Bleeding risk; with PEX/steroids |
| Methylprednisolone | Glucocorticoid | Hours | Immunosuppression | Hyperglycemia, infection |
Prognosis / Complications
- Outcome depends on timeliness of diagnosis and definitive therapy
Patient Education / Counseling
- Explain red flags, adherence, and follow‑up plan
References
Use the Library, QBank, CCS, and analytics in one study workflow.
You just reviewed Immune TTP — ADAMTS13, Plasma Exchange, Steroids, and Caplacizumab. MDSteps helps you turn that review into exam-style practice, missed-item flashcards, and a readiness dashboard that shows what to study next.
- 16,000+ USMLE-style questions across Step 1, Step 2, and Step 3
- CCS simulator with timed orders, live vitals, and case feedback
- Depth-on-Demand™ explanations and Anki-exportable flashcards
- Library + QBank + analytics for $27/month or $299 lifetime